Meningococcal serogroup W135 in the African meningitis belt: epidemiology, immunity and vaccines

Mueller, Judith E.; Borrow, Raymond; Gessner, Bradford D.

doi:10.1586/14760584.5.3.319

Cited by 37 publications

(31 citation statements)

References 121 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The current recommendation is for an initial dose during the first 12 and African Meningitis belt at the beginning of the 21st century, and there is also some evidence that it is now becoming more frequently observed as a cause of disease in Latin America. [66][67][68] Therefore it may remain important to continue to consider the need to provide protection against W-135 disease.…”

Section: Methodsmentioning

confidence: 99%

The changing epidemiology of meningococcal disease in North America 1945–2010

Baccarini

Ternouth²,

Wieffer³

et al. 2013

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

The changing epidemiology of meningococcal disease in North America 1945–2010

Baccarini

Ternouth²,

Wieffer³

et al. 2013

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

“…The seroprevalence of W135 reported as baseline measurement from various clinical trials was summarized by Mueller et al (24) and was found to vary more by country and study than by age group. This reflects differences in the assays used by different laboratories, in particular the target strains (5) and local conditions that lead to higher seroprevalence, specifically the degree of carriage and transmission and also the prevalence of locally occurring cross-reactive antigens.…”

Section: Fig 2 Percentage Of Individuals With Rsba Titers Of ն8 Againmentioning

confidence: 99%

Seroprevalence of Serum Bactericidal Antibodies against Group W135 and Y Meningococci in England in 2009

Trotter

Findlow

Borrow

2012

Clin Vaccine Immunol

View full text Add to dashboard Cite

Serological surveillance has been used in the United Kingdom to inform vaccine policy for several infections, including those with group C meningococci. Meningococcal conjugate vaccines, containing capsular groups A, W135, and Y in addition to C, are now available, but their use in the United Kingdom is restricted to at-risk groups and travelers to areas of endemicity. The aim of this study was to establish a baseline for natural immunity for groups W135 and Y. Serum samples collected in 2009 from individuals of all ages were obtained from the Health Protection Agency Seroepidemiology Unit, which collects residual sera from participating laboratories across the country. Serum bactericidal antibody (SBA) activity against two reference strains, representing groups Y (strain M03 241125) and W135 (strain M01 240070), was determined with 1,191 sera using a standardized complement-mediated SBA assay, with complement derived from baby rabbits (rSBA). The age-specific geometric mean titers (GMTs) and percentages of individuals with rSBA titers of >8 were calculated, together with 95% confidence intervals (CI). Overall, 18.4% and 19.6% had rSBA titers of >8 for groups W135 and Y, respectively. Antibody prevalence varied by age. In general, rSBA titers were low for younger children, with serum samples from 7% and 13% of children under 5 years achieving titers of >8 against groups W135 and Y, respectively. GMTs peaked for 20-to 24-year-olds for group W135 (GMT, 7.1; 95% CI, 4.7, 10.9) and for 30-to 44-year-olds for group Y (GMT, 8.6; 95% CI, 5.9, 12.7). Unlike seroprevalence against group B meningococci, there was not an obvious peak in SBA titers in samples from teenagers. Natural immunity against group W135 and Y meningococci in England appears to be low.

show abstract

“…In 2010, a low cost serogroup A polysaccharide-protein conjugate vaccine (MenAfriVac) was introduced [2–4]. The vaccine conferred protection against invasive disease [5, 6] as well as asymptomatic nasopharyngeal carriage of serogroup A strains [7–9], but failed to curtail disease or carriage by strains with serogroups C, X, or W, which also cause epidemics in the region [10–15]. Meningococcal A,C,Y and W conjugate vaccines, which are available in industrialized countries, can prevent epidemics caused by these strains.…”

Section: Introductionmentioning

confidence: 99%

A meningococcal NOMV-FHbp vaccine for Africa elicits broader serum bactericidal antibody responses against serogroup B and non-B strains than a licensed serogroup B vaccine

Pajón

Lujan

Granoff

2016

Vaccine

View full text Add to dashboard Cite

Background Meningococcal epidemics in Sub-Sahara caused by serogroup A strains are controlled by a group A polysaccharide conjugate vaccine. Strains with serogroups C, W and X continue to cause epidemics. Protein antigens in licensed serogroup B vaccines are shared among serogroup B and non-B strains. Purpose Compare serum bactericidal antibody responses elicited by an investigational native outer membrane vesicle vaccine with over-expressed Factor H binding protein (NOMV-FHbp) and a licensed serogroup B vaccine (MenB-4C) against African serogroup A, B, C, W and X strains. Methods Human Factor H (FH) transgenic mice were immunized with NOMV-FHbp prepared from a mutant African meningococcal strain containing genetically attenuated endotoxin and a mutant sub-family B FHbp antigen with low FH binding, or with MenB-4C, which contains a recombinant sub-family B FHbp antigen that binds human FH, and three other antigens, NHba, NadA and PorA P1.4, capable of eliciting bactericidal antibody. Results The NOMV-FHbp elicited serum bactericidal activity against 12 of 13 serogroup A, B, W or X strains from Africa, and four isogenic serogroup B mutants with subfamily B FHbp sequence variants. There was no activity against a serogroup B mutant with sub-family A FHbp, or two serogroup C isolates from a recent outbreak in Northern Nigeria, which were mismatched for both PorA and sub-family of the FHbp vaccine antigen. For MenB-4C, NHba was expressed by all 16 African isolates tested, FHbp sub-family B in 13, and NadA in five. However, MenB-4C elicited titers ≥1:10 against only one isolate, and against only two of four serogroup B mutant strains with sub-family B FHbp sequence variants. Conclusions NOMV-FHbp has greater potential to confer serogroup-independent protection in Africa than the licensed MenB-4C vaccine. However, the NOMV-FHbp vaccine will require inclusion of sub-family A FHbp for coverage against recent serogroup C strains causing outbreaks in Northern Nigeria.

show abstract

Meningococcal serogroup W135 in the African meningitis belt: epidemiology, immunity and vaccines

Cited by 37 publications

References 121 publications

The changing epidemiology of meningococcal disease in North America 1945–2010

The changing epidemiology of meningococcal disease in North America 1945–2010

Seroprevalence of Serum Bactericidal Antibodies against Group W135 and Y Meningococci in England in 2009

A meningococcal NOMV-FHbp vaccine for Africa elicits broader serum bactericidal antibody responses against serogroup B and non-B strains than a licensed serogroup B vaccine

Contact Info

Product

Resources

About